A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma

Journal:
Blood
Published:
Affiliations:
25
Authors:
23
Institutions Authors Share
Takeda Pharmaceuticals U.S.A., Inc., United States of America (USA)
6.000000
0.26
University of Nebraska Medical Center (UNMC), United States of America (USA)
1.000000
0.04
Levine Cancer Institute, Atrium Health, United States of America (USA)
1.000000
0.04
McMaster University, Canada
1.000000
0.04
Oslo University Hospital (OUS), Norway
1.000000
0.04
University College Hospital (UCH), United Kingdom (UK)
1.000000
0.04
Montefiore Medical Center, Einstein, United States of America (USA)
1.000000
0.04
Hadassah Medical Center, HUJI, Israel
1.000000
0.04
Johns Hopkins University (JHU), United States of America (USA)
1.000000
0.04
Hôpital Necker-Enfants Malades, France
1.000000
0.04
University Hospital Nantes (CHU de Nantes), France
1.000000
0.04
Centre Hospitalier Universitaire de Lille (CHU Lille), France
1.000000
0.04
Highlands Oncology, United States of America (USA)
1.000000
0.04
Dana-Farber Cancer Institute (DFCI), United States of America (USA)
1.000000
0.04
Abramson Cancer Center, Penn, United States of America (USA)
1.000000
0.04
National and Kapodistrian University of Athens (UOA), Greece
0.500000
0.02
Korea University, South Korea
0.500000
0.02
Istinye University (ISU), Turkey
0.500000
0.02
Liv Hospital Ankara, Turkey
0.500000
0.02
Chaim Sheba Medical Center at Tel HaShomer, Israel
0.500000
0.02
Tel Aviv University (TAU), Israel
0.500000
0.02